Update on the use of aromatase inhibitors in breast cancer (Q36613881)

15 August 2017

1 reference

title

Update on the use of aromatase inhibitors in breast cancer (English)

1 reference

15 August 2017

1 reference

Robert W Brueggemeier

series ordinal

1

1 reference

PubMed ID

17020418

15 August 2017

language of work or name

English

0 references

publication date

1 October 2006

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

1 reference

15 August 2017

7

1 reference

15 August 2017

14

1 reference

15 August 2017

1919-1930

1 reference

Organization of the human aromatase p450 (CYP19) gene

15 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Human aromatase in high yield and purity by perfusion chromatography and its characterization by difference spectroscopy and mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Aromatase--a brief overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Validation of new aromatase monoclonal antibodies for immunohistochemistry: progress report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Regulation of arachidonic acid metabolism, aromatase activity and growth in human breast cancer cells by interleukin-1beta and phorbol ester: dissociation of a mediatory role for prostaglandin E2 in the autocrine control of cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Nonsteroidal antiinflammatory drugs and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Aromatase and COX-2 expression in human breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Prostaglandin E2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Binding characteristics of aromatase inhibitors and phytoestrogens to human aromatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Biochemical and molecular aspects of aromatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Aromatase inhibitors--mechanisms of steroidal inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Mechanism and inhibition of cytochrome P-450 aromatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Aromatase and its inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Use of aromatase inhibitors in breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Aromatase inhibitors in the treatment of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Metabolism of the aromatase inhibitor 4-hydroxyandrostenedione in vivo. Identification of the glucuronide as a major urinary metabolite in patients and biliary metabolite in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

A new irreversible aromatase inhibitor, 6-methylenandrosta-1,4-diene-3,17-dione (FCE 24304): antitumor activity and endocrine effects in rats with DMBA-induced mammary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

The minimal effective exemestane dose for endocrine activity in advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Pharmacology and clinical experience with exemestane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Comparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Arimidex: a potent and selective fourth-generation aromatase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Breast cancer prevention—clinical trials strategies involving aromatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients1Accepted as a poster presentation to the 34th Annual Meeting of the American Society of Clinical Oncology, May 1998, Los Ang

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1919

10.1517/14656566.7.14.1919

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

17020418